How much funding has Atsena raised?

Atsena has raised $229.5M in total funding, most recently a Series C round.

Who are Atsena's investors?

Atsena's investors include Hatteras Venture Partners, Bain Capital Life Sciences, Wellington Management, Sofinnova Investments, Lightstone Ventures, Abingworth Bioventures.

Where is Atsena headquartered?

Atsena is headquartered in Durham, North Carolina, United States.

What industry is Atsena in?

Atsena operates in Biotech, Healthcare.

Atsena

Focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness

Durham, United States · Founded 2020 · $229.5M raised

Biotech

Healthcare

Headquarters: Durham, North Carolina
Employees: 11–50
Founded: 2020
Business Model: B2B

Total Funding: $229.5M
Last Round: $150.0M Series CApr 2025
Rounds: 3

About

Atsena Therapeutics is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness caused by inherited retinal diseases (IRDs). Its pipeline is powered by novel adeno-associated virus (AAV) technology, including proprietary spreading capsids, tailored to overcome the anatomical hurdles of ocular gene delivery. Lead programs include ATSN-201 in a Phase I/II trial for X-linked retinoschisis (XLRS) and ATSN-101 in a Phase I/II trial for Leber congenital amaurosis type 1 (LCA1). The company was founded by pioneers in ocular gene therapy and is headquartered in Durham, North Carolina.

Summary

Atsena is a Biotech company based in Durham, United States, founded in 2020. It has raised $229.5M in total across 3 rounds, most recently a $150.0M Series C round in Apr 2025. Investors include Hatteras Venture Partners, Bain Capital Life Sciences and Wellington Management.